Analysis Hikma Pharmaceuticals plc. (HKMPF)
5/25/2024
Analysis of Hikma Pharmaceuticals plc. (HKMPF)
Hikma Pharmaceuticals plc (HKMPF) has been showing a consistent uptrend in its stock price over the past few days. The Relative Strength Index (RSI) is indicating overbought conditions with a value of 72.05691, suggesting that the stock may be due for a correction.The Moving Average Convergence Divergence (MACD) indicator is showing a positive trend, with the MACD line above the signal line and a positive MACD histogram. This indicates bullish momentum in the stock.
In terms of moving averages, the stock price is above the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA). This further supports the bullish outlook for Hikma Pharmaceuticals plc.
Overall, based on the technical indicators, Hikma Pharmaceuticals plc appears to be in a strong bullish trend, but investors should be cautious of a potential correction due to the overbought RSI reading.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management.
3. The gross profit margin has remained relatively stable over the years, suggesting efficient cost control measures.
4. Earnings before interest and taxes (EBIT) have shown an upward trend, reaching $117.7 billion in 2023 from $69.9 billion in 2020.
5. Net income has also been increasing consistently, reaching $97 billion in 2023 from $57.4 billion in 2020.
6. The company has been able to maintain a healthy EBITDA margin over the years, indicating operational efficiency.
7. Diluted earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trajectory.
8. The company's effective tax rate has remained relatively stable, indicating consistent tax planning strategies.
9. Overall, the financial performance of the company seems to be strong, with a focus on revenue growth and cost management.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Earnings
The company's results for the following dates are as follows:- April 30, 2025: Time Not Supplied
- February 27, 2025: Transfer Agent
- January 31, 2025: After Hours
- October 31, 2024: Time Not Supplied
- August 1, 2024: Time Not Supplied (EPS Estimate: 1.33)
Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits for a specific company. Here is a summary of the key information:1. Financials:
- Cash Flow: Operating cash flow (TTM) is $110,563,000,320 and levered free cash flow (TTM) is $84,726,874,112.
- Balance Sheet: Total cash (MRQ) is $67,150,000,128, total debt (MRQ) is $104,590,000,128, current ratio (MRQ) is 1.037, book value per share (MRQ) is $4.837, total cash per share (MRQ) is $4.379, and total debt to equity ratio (MRQ) is 140.968.
- Profit Margin: 26.306%
- Fiscal Year Ends: September 30, 2023
- Income Statement: EBITDA is $131,393,000,000, revenue (TTM) is $381,623,009,280, diluted EPS (TTM) is $6.44, gross profit (TTM) is $169,148,000,000, revenue per share (TTM) is $24.537, net income to common (TTM) is $100,389,003,264, quarterly revenue growth is -4.3%, and quarterly earnings growth YoY is -2.2%.
- Operating Margin: 30.743%
- Return on Assets (TTM): 22.073999%
- Return on Equity (TTM): 147.25%
2. Stock Statistics:
- Short Ratio: 1.66
- Float Shares: 15,308,320,742
- Shares Short: 94,308,265
- Average 10-Day Volume: 52,903,608
- Average 90-Day Volume: 62,823,269
- Shares Outstanding: 15,334,099,968
- Percent Held by Insiders: 5.22%
- Percent Held by Institutions: 57.555%
- Short Percent of Shares Outstanding: 0.62%
3. Valuation Metrics:
- PEG Ratio: 26.213001
- Forward P/E: 26.213001
- Trailing P/E: 29.428572
- Enterprise Value: $2,948,462,018,560
- Price to Book (MRQ): 39.181313
- Price to Sales (TTM): 7.6151557
- Enterprise to EBITDA: 22.745
- Enterprise to Revenue: 7.726
- Market Capitalization: $2,906,118,684,672
4. Stock Price Summary:
- Beta: 1.264
- 50-Day Moving Average: $173.6936
- 200-Day Moving Average: $180.7906
- 52-Week Low: $164.08
- 52-Week High: $199.62
- 52-Week Change: 8.253%
5. Dividends and Splits:
- Payout Ratio: 14.93%
- Dividend Date: May 16, 2024
- Last Split Date: August 31, 2020
- Ex-Dividend Date: May 10, 2024
- Last Split Factor: 4-for-1 split
- Forward Annual Dividend Rate: $1
- 5-Year Average Dividend Yield: 0.73%
- Forward Annual Dividend Yield: 0.5266761603816345%
- Trailing Annual Dividend Rate: $0.97
- Trailing Annual Dividend Yield: 0.5108758755701854%
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
5. Investing activities include the sale and purchase of investments, capital expenditures, and acquisitions.
6. The end cash position has been fluctuating, but generally, the company has maintained a healthy cash balance.
7. Stock-based compensation has been a significant non-cash item in the operating activities section.
8. The company has been managing its cash flow effectively, with a focus on maintaining liquidity while also investing in growth opportunities.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39
Based on these estimates, we can see a generally positive outlook with an expected increase in earnings per share for both the next quarter and the next year compared to the previous periods. The number of analysts providing estimates also indicates a strong interest in the company's performance.
Revenue estimate
Based on analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates indicate a generally positive outlook for the company's sales performance, with expected growth in both the quarterly and annual sales figures.
Growth estimates
Based on the consensus estimates provided:- The company is expected to grow at a rate of 7.5% in the current year.
- The growth rate is projected to increase to 5.6% in the current quarter and further to 4.8% in the next quarter.
- Over the next 5 years, the company is expected to grow at an average annual rate of 11%.
- However, the company has experienced a higher growth rate in the past 5 years, with an average annual growth rate of 20.15%.
Overall, the company is expected to maintain a steady growth trajectory in the near future, with a slightly lower growth rate compared to the past 5 years.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, it can be observed that the analysts have a relatively positive outlook on the future price of the security, with a median price of $200. However, it is important to note that there is a wide range between the low and high forecasts, indicating some uncertainty in the predictions. The current price of $191.57 is below both the average and median forecast, suggesting a potential upside according to analysts' expectations.
MACD of HKMPF
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
